Biohaven - BHVN Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings or view top-rated stocks.

9 brokerages have issued twelve-month price objectives for Biohaven's stock. Their BHVN share price forecasts range from $21.00 to $148.50. On average, they anticipate the company's stock price to reach $48.75 in the next twelve months. This suggests a possible upside of 256.9% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.

Biohaven's stock was trading at $13.88 at the start of the year. Since then, BHVN shares have decreased by 1.6% and is now trading at $13.66.
View the best growth stocks for 2023 here.

Biohaven saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 5,940,000 shares, a decrease of 7.2% from the February 28th total of 6,400,000 shares. Based on an average daily trading volume, of 996,300 shares, the days-to-cover ratio is presently 6.0 days. Approximately 10.3% of the shares of the stock are short sold.
View Biohaven's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our BHVN earnings forecast.

Biohaven Ltd. (NYSE:BHVN) announced its quarterly earnings results on Monday, November, 8th. The company reported ($2.63) earnings per share for the quarter, missing analysts' consensus estimates of ($2.40) by $0.23. The firm had revenue of $135.74 million for the quarter, compared to the consensus estimate of $128.40 million. The business's revenue was up 668.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($3.27) earnings per share.

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Vanguard Russell 2000 Growth ETF (VTWG), Vanguard Russell 2000 Value ETF (VTWV), Inspire Global Hope ETF (BLES), Principal Healthcare Innovators ETF (BTEC) and BlackRock Future Health ETF (BMED).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHVN stock can currently be purchased for approximately $13.66.

Biohaven (NYSE:BHVN) has a market capitalization of $931.75 million and generates $462.51 million in revenue each year. The company earns $-570,280,000.00 in net income (profit) each year or ($14.25) on an earnings per share basis.

The company employs 928 workers across the globe.

Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via email at jennifer.porcelli@biohavenpharma.com.